Evidence map›Paper›PMID 40528408›Full record

ArticleAnnals of laboratory medicine2025

Clinical Utility of Monitoring Circulating Tumor DNA Using a Targeted Next-generation Sequencing Panel in Patients with Colorectal Cancer.

Hyoeun Shim, Soobeen Heo, Jiyu Sun, Moon Ki Choi, Sung Chan Park, Chang Won Hong, Seong Hoon Kim, Seog-Yun Park, Sun-Young Kong, Ji Yeon Baek

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of laboratory medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Hyoeun ShimDepartment of Laboratory Medicine, National Cancer Center, Goyang, Korea.ORCID https://orcid.org/0000-0002-8985-0882
Soobeen HeoTargeted Therapy Branch, Research Institute, National Cancer Center, Goyang, Korea.ORCID https://orcid.org/0009-0005-4087-5519
Jiyu SunIntegrated Biostatistics Branch, Division of Cancer Data Science, National Cancer Center, Goyang, Korea.ORCID https://orcid.org/0000-0002-4010-2023
Moon Ki ChoiCenter for Colorectal Cancer, National Cancer Center, Goyang, Korea.ORCID https://orcid.org/0000-0002-1749-9675
Sung Chan ParkCenter for Colorectal Cancer, National Cancer Center, Goyang, Korea.ORCID https://orcid.org/0000-0003-3949-7862
Chang Won HongCenter for Colorectal Cancer, National Cancer Center, Goyang, Korea.ORCID https://orcid.org/0000-0003-3577-9264
Seong Hoon KimOrgan Transplantation Center, National Cancer Center, Goyang, Korea.ORCID https://orcid.org/0000-0001-7921-1801
Seog-Yun ParkDepartment of Pathology, National Cancer Center, Goyang, Korea.ORCID https://orcid.org/0000-0002-5704-646X
Sun-Young KongDepartment of Laboratory Medicine, National Cancer Center, Goyang, Korea.ORCID https://orcid.org/0000-0003-0620-4058
Ji Yeon BaekCenter for Colorectal Cancer, National Cancer Center, Goyang, Korea.ORCID https://orcid.org/0000-0002-5068-5891

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Circulating tumor DNA (ctDNA) profiling from peripheral blood allows relatively noninvasive monitoring of solid tumors; however, its utility post-surgery or chemotherapy in colorectal cancer remains underexplored. We evaluated the clinical implications of a ctDNA next-generation sequencing (NGS) panel post-surgery or chemotherapy in patients with colorectal cancer. Methods: We collected samples from 23 patients with colorectal cancer (17 men, median age 65 yrs) at baseline and post-surgery or chemotherapy at the National Cancer Center, Korea, between January 2021 and September 2023. ctDNA was analyzed using an NGS panel including 46 genes, and variant allele frequencies (VAFs) were determined. Follow-up samples were analyzed using the NGS panel or droplet digital PCR (ddPCR) when probes were available. Clinical status was compared with ctDNA results, and survival was analyzed using a time-dependent Cox model. Results: Mutations were identified in 13 out of 14 patients (92.8%) with stage II/III cancer and in all nine patients (100%) with stage IV cancer. Mutations were detected in Conclusions: The detection of and an increase in

Indexed as

Circulating Tumor DNAColorectal NeoplasmsHigh-Throughput Nucleotide SequencingAdenomatous Polyposis Coli ProteinAdultAgedAged, 80 and overBiomarkers, TumorClass I Phosphatidylinositol 3-KinasesFemaleGene FrequencyHumansMaleMiddle AgedMutationNeoplasm StagingAdenomatous Polyposis Coli ProteinBiomarkers, TumorCirculating Tumor DNAClass I Phosphatidylinositol 3-KinasesKRAS protein, humanProto-Oncogene Proteins p21(ras)Tumor Suppressor Protein p53Circulating tumor DNAColorectal cancerPrognosis

Identifiers

PMID40528408
PMCPMC12187491

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.